vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $18.6M, roughly 1.1× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -541.1%, a 606.8% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 86.1%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 56.1%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
AGIO vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $18.6M |
| Net Profit | $-108.0M | $12.3M |
| Gross Margin | 90.6% | — |
| Operating Margin | -608.9% | 56.3% |
| Net Margin | -541.1% | 65.7% |
| Revenue YoY | 86.1% | 1808.5% |
| Net Profit YoY | -11.9% | 376.5% |
| EPS (diluted) | $-1.86 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $18.6M | ||
| Q3 25 | $12.9M | $334.0K | ||
| Q2 25 | $12.5M | $1.4M | ||
| Q1 25 | $8.7M | $257.0K | ||
| Q4 24 | $10.7M | $977.0K | ||
| Q3 24 | $9.0M | $660.0K | ||
| Q2 24 | $8.6M | $736.0K | ||
| Q1 24 | $8.2M | $1.4M |
| Q4 25 | $-108.0M | $12.3M | ||
| Q3 25 | $-103.4M | $-8.6M | ||
| Q2 25 | $-112.0M | $-6.9M | ||
| Q1 25 | $-89.3M | $-5.4M | ||
| Q4 24 | $-96.5M | — | ||
| Q3 24 | $947.9M | $-2.8M | ||
| Q2 24 | $-96.1M | $-14.5M | ||
| Q1 24 | $-81.5M | $411.0K |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 92.3% | — |
| Q4 25 | -608.9% | 56.3% | ||
| Q3 25 | -907.4% | -2516.5% | ||
| Q2 25 | -1020.1% | -701.0% | ||
| Q1 25 | -1222.0% | -3350.2% | ||
| Q4 24 | -1165.3% | — | ||
| Q3 24 | -1146.9% | -1563.6% | ||
| Q2 24 | -1228.3% | -1255.0% | ||
| Q1 24 | -1124.3% | -692.5% |
| Q4 25 | -541.1% | 65.7% | ||
| Q3 25 | -803.1% | -2572.2% | ||
| Q2 25 | -899.4% | -504.8% | ||
| Q1 25 | -1023.3% | -2097.7% | ||
| Q4 24 | -899.6% | — | ||
| Q3 24 | 10574.7% | -425.5% | ||
| Q2 24 | -1115.7% | -1964.4% | ||
| Q1 24 | -995.8% | 29.9% |
| Q4 25 | $-1.86 | $0.25 | ||
| Q3 25 | $-1.78 | $-0.17 | ||
| Q2 25 | $-1.93 | $-0.14 | ||
| Q1 25 | $-1.55 | $-0.11 | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $16.22 | $-0.06 | ||
| Q2 24 | $-1.69 | $-0.30 | ||
| Q1 24 | $-1.45 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $49.4M |
| Total Assets | $1.3B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | $40.0M | ||
| Q3 25 | $92.7M | $37.9M | ||
| Q2 25 | $80.9M | $44.8M | ||
| Q1 25 | $79.0M | $40.6M | ||
| Q4 24 | $76.2M | $59.3M | ||
| Q3 24 | $253.7M | $68.8M | ||
| Q2 24 | $84.5M | $73.0M | ||
| Q1 24 | $118.8M | $80.2M |
| Q4 25 | $1.2B | $49.4M | ||
| Q3 25 | $1.3B | $36.4M | ||
| Q2 25 | $1.4B | $44.5M | ||
| Q1 25 | $1.5B | $50.5M | ||
| Q4 24 | $1.5B | $55.1M | ||
| Q3 24 | $1.6B | $58.5M | ||
| Q2 24 | $660.5M | $60.4M | ||
| Q1 24 | $743.9M | $74.1M |
| Q4 25 | $1.3B | $59.0M | ||
| Q3 25 | $1.4B | $51.1M | ||
| Q2 25 | $1.5B | $60.7M | ||
| Q1 25 | $1.6B | $67.9M | ||
| Q4 24 | $1.7B | $90.6M | ||
| Q3 24 | $1.8B | $99.0M | ||
| Q2 24 | $773.1M | $107.8M | ||
| Q1 24 | $849.7M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $18.4M |
| Free Cash FlowOCF − Capex | $-97.3M | — |
| FCF MarginFCF / Revenue | -487.5% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $18.4M | ||
| Q3 25 | $-88.2M | $-8.7M | ||
| Q2 25 | $-77.1M | $-7.5M | ||
| Q1 25 | $-111.5M | $-7.5M | ||
| Q4 24 | $-133.2M | $-24.0M | ||
| Q3 24 | $-84.2M | $765.0K | ||
| Q2 24 | $-72.6M | $-10.9M | ||
| Q1 24 | $-99.9M | $-4.0M |
| Q4 25 | $-97.3M | — | ||
| Q3 25 | $-89.7M | — | ||
| Q2 25 | $-78.0M | — | ||
| Q1 25 | $-112.3M | — | ||
| Q4 24 | $-134.1M | — | ||
| Q3 24 | $-84.6M | — | ||
| Q2 24 | $-72.7M | — | ||
| Q1 24 | $-100.0M | — |
| Q4 25 | -487.5% | — | ||
| Q3 25 | -696.5% | — | ||
| Q2 25 | -626.2% | — | ||
| Q1 25 | -1286.4% | — | ||
| Q4 24 | -1250.1% | — | ||
| Q3 24 | -944.2% | — | ||
| Q2 24 | -844.4% | — | ||
| Q1 24 | -1221.2% | — |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 4.7% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGIO
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
